var data={"title":"Cidofovir: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Cidofovir: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5899?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=cidofovir-drug-information\" class=\"drug drug_general\">see &quot;Cidofovir: Drug information&quot;</a> and <a href=\"topic.htm?path=cidofovir-patient-drug-information\" class=\"drug drug_patient\">see &quot;Cidofovir: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708672\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Nephrotoxicity:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Renal impairment is the major toxicity of cidofovir. Cases of acute renal failure resulting in dialysis and/or contributing to death have occurred with as few as 1 or 2 doses of cidofovir. To reduce possible nephrotoxicity, IV prehydration with normal saline and administration of probenecid must be used with each cidofovir infusion. Renal function (serum creatinine and urine protein) must be monitored within 48 hours prior to each dose of cidofovir and the dose of cidofovir modified for changes in renal function as appropriate. Cidofovir is contraindicated in patients who are receiving other nephrotoxic agents.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Neutropenia:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:2em;\">Neutropenia has been observed in association with cidofovir treatment. Therefore, neutrophil counts should be monitored during cidofovir therapy.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Appropriate use:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:2em;\">Cidofovir is indicated only for the treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS).</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Carcinogenic/teratogenic:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:2em;\">In animal studies, cidofovir was carcinogenic, teratogenic and caused hypospermia. </p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F151289\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Vistide [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046274\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antiviral Agent, Parenteral</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046266\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=cidofovir-drug-information\" class=\"drug drug_general\">see &quot;Cidofovir: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note:</b> Administration of cidofovir should be accompanied by concomitant oral probenecid and intravenous normal saline hydration; various regimens have been reported (Anderson 2008; Bhadri 2009; Cesaro 2005; Doan 2007; Williams 2009; Yusuf 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Hydration:</i> IV: 20 mL/kg of 0.9% sodium chloride (maximum: 1,000 mL) administered for 1 hour before cidofovir infusion and 20 mL/kg of 0.9% sodium chloride (maximum: 1,000 mL) over 1 hour during cidofovir infusion, followed by 2 hours of maintenance fluids <b>or</b> increase the maintenance fluid infusion rate to 3 times the maintenance rate for 1 hour before cidofovir infusion and continuing until 1 hour after, then decrease to 2 times the maintenance fluid rate for the subsequent 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Probenecid:</i> Oral: 25 to 40 mg/kg/dose (maximum dose: 2,000 mg) administered 3 hours before cidofovir infusion and 10 to 20 mg/kg/dose (maximum dose: 1,000 mg) at 2 to 3 hours and 8 to 9 hours after cidofovir infusion <b>or</b> 1,000 or 1,250 mg/m<sup>2</sup>/dose administered 3 hours prior to cidofovir, followed by 500 to 1,250 mg/m<sup>2</sup>/dose 1 to 2 hours and 8 hours after completion</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Adenovirus infection, posthematopoietic stem cell transplant; treatment:</b> Limited data available; optimal dose not defined; specific regimens may vary (Bhadri 2009; Legrand 2001; Yusuf 2006): Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Induction: IV: 5 mg/kg/dose once weekly for 2 to 3 consecutive weeks (with hydration and probenecid)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Maintenance: IV: 5 mg/kg/dose once every 2 weeks <b>or</b> 3 mg/kg/dose once weekly (with hydration and probenecid) until consecutive negative adenovirus samples. <b>Note:</b> In one study, patients requiring prolonged treatment courses were switched from 3 mg/kg/dose once weekly to 1 mg/kg/dose given 3 times/week (Bhadri 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Adenovirus infection, postlung transplant; treatment:</b> Very limited data available: Infants &ge;6 months and Children &lt;3 years: IV: 1 mg/kg/dose every other day or 3 times weekly for 4 consecutive weeks (with hydration and probenecid); dosing from a case series (n=4, age range: 0.5 to 2.6 years) (Doan 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>BK virus allograft nephropathy:</b> Limited data available: Children and Adolescents: IV: Initial dose: 0.25 mg/kg/dose every 2 to 3 weeks; dose may be increased if BK virus PCR counts do not decrease 1 log fold to a maximum dose of 1 mg/kg/dose. Dosing based on reported experience from two case series of 10 renal transplant patients (ages: 5 to 21 years). The reported hydration was D5<sup>1</sup>/<sub>2</sub>NS or D5<sup>1</sup>/<sub>4</sub>NS for 2 hours before cidofovir and for 2 hours following the infusion; cidofovir was infused over 2 hours and no probenecid was used (Araya 2008; Araya 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>BK virus hemorrhagic cystitis after stem cell or bone marrow transplant:</b> Limited data available; optimal dose not established: Children and Adolescents: IV: 5 mg/kg/dose once weekly for 2 to 4 weeks, followed by 5 mg/kg/dose every other week given with probenecid and adequate hydration until cystitis resolved is the most commonly reported dose (Cesaro 2009, Gaziev 2010, Megged 2011). Others have described lower doses of 0.5 to 1 mg/kg/dose given once weekly with or without probenecid (Cesaro 2009; Cesaro 2013; Faraci 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cytomegalovirus (CMV) infection:</b> Limited data available. IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Allogeneic stem cell transplantation recipients:</i> Treatment: Children and Adolescents: Dosing based on reported experience in 10 pediatric patients (2 to 14 years); most patients received cidofovir as second-line therapy following allogeneic stem cell transplantation (Cesaro 2005).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Induction: 5 mg/kg/dose once weekly for 2 consecutive weeks (with hydration, probenecid and antiemetic)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maintenance: 3 to 5 mg/kg/dose once every 2 weeks for 2 to 4 doses (with hydration, probenecid, and antiemetic)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>HIV-exposed/-positive patients:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CMV retinitis: Treatment: Adolescents [DHHS (adult) 2013]:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Induction: 5 mg/kg/dose once weekly for 2 consecutive weeks (with hydration and probenecid)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Maintenance: 5 mg/kg/dose every other week (with hydration and probenecid)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Secondary prophylaxis: 5 mg/kg/dose every other week (with hydration and probenecid) [DHHS (adult/pediatric) 2013]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Respiratory papillomatosis, recurrent:</b> Limited data available: Children and Adolescents: Intralesional: 7.5 mg/mL every 2 weeks until complete remission (Naiman 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Cytomegalovirus (CMV) retinitis: Note:</b> Administration of cidofovir should be accompanied by concomitant oral probenecid and intravenous normal saline hydration</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Induction: IV: 5 mg/kg/dose once weekly for 2 consecutive weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Maintenance: IV: 5 mg/kg/dose once every 2 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Concomitant therapy:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Probenecid:</i> 2 g 3 hours prior to cidofovir dose, then 1 g at 2 hours and 8 hours after completion of the infusion</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Hydration:</i> Patients should also receive 1 L of NS intravenously infused over 1 to 2 hours immediately prior to each cidofovir infusion. If tolerated, a second liter may be administered over 1 to 3 hours at the start of cidofovir infusion or immediately following infusion.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> High flux hemodialysis removes ~75%</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants &ge;6 months, Children, and Adolescents: <i>Adenovirus post-transplant </i>(Yusuf 2006): S<sub>cr</sub> &gt;1.5 mg/dL, CrCl &lt;90 mL/minute/1.73 m<sup>2</sup>, and &gt;2+ proteinuria: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Induction: 1 mg/kg/dose 3 times weekly on alternate days for 2 consecutive weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maintenance: 1 mg/kg/dose every other week</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Preexisting renal impairment:</i> S<sub>cr </sub>&gt;1.5 mg/dL, CrCl &le;55 mL/minute or a urine protein &ge;100 mg/dL (&ge;2+ proteinuria): Use is contraindicated</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>During therapy:</i> If the serum creatinine increases by 0.3 to 0.4 mg/dL above baseline: Reduce the cidofovir dose to 3 mg/kg; discontinue cidofovir therapy for increases &ge;0.5 mg/dL above baseline or development of &ge;3+ proteinuria.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F151268\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vistide: 75 mg/mL (5 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 75 mg/mL (5 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F151253\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046277\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: Administer by IV infusion over 1 hour.  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49130930\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 2]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) for preparation. Double gloving, a gown, and (if dosage form allows) CSTDs are required during administration (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F151283\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store intact vials at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Admixtures in D5<sup>1</sup>/<sub>4</sub>NS, D5W, or NS may be stored for &le;24 hours under refrigeration; however, admixtures must be administered within 24 hours of preparation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046276\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS) (FDA approved in adults). Has also been used for treatment of ganciclovir-resistant CMV, foscarnet-resistant CMV, and adenovirus infections in immunocompromised patients; has also been used intralesionally for the treatment of recurrent respiratory papillomatosis  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F151319\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Cardiac disease, cardiac failure, cardiomyopathy, edema, orthostatic hypotension, shock, syncope, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Agitation, amnesia, anxiety, chills, confusion, convulsions, dizziness, hallucination, headache, insomnia, malaise, pain, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Alopecia, skin discoloration, skin photosensitivity, skin rash, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Endocrine &amp; metabolic: Adrenocortical insufficiency, decreased serum bicarbonate, Fanconi's syndrome</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Abdominal pain, anorexia, aphthous stomatitis, colitis, constipation, diarrhea, dysphagia, fecal incontinence, gastritis, gastrointestinal hemorrhage, gingivitis, melena, nausea, oral candidiasis, proctitis, stomatitis, tongue discoloration, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Genitourinary: Nephrotoxicity, proteinuria, urinary incontinence</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Anemia, hypochromic anemia, immune thrombocytopenia, leukocytosis, leukopenia, lymphadenopathy, neutropenia, pancytopenia, pseudolymphoma, splenomegaly, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hepatic: Abnormal liver function tests, hepatic disease, hepatic necrosis, hepatomegaly, hepatosplenomegaly, jaundice</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hypersensitivity: Hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Infection: Infection, sepsis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Local: Injection site reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Tremor, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ophthalmic: Amblyopia, blindness, cataract, conjunctivitis, corneal lesion, decreased intraocular pressure, diplopia, iritis, uveitis, visual disturbance</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Otic: Hearing loss</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Renal: Increased serum creatinine</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Cough, dyspnea, pneumonia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Rare but important or life-threatening: Hepatic failure, metabolic acidosis, pancreatitis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F151274\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to cidofovir or any component of the formulation; history of clinically-severe hypersensitivity to probenecid or other sulfa-containing medications; serum creatinine &gt;1.5 mg/dL; CrCl &le;55 mL/minute; urine protein &ge;100 mg/dL (&ge;2+ proteinuria); use with or within 7 days of nephrotoxic agents; direct intraocular injection</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F151257\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Carcinogenic/teratogenic: <b>[US Boxed Warning]: Possibly carcinogenic and teratogenic based on animal data. May cause hypospermia.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Metabolic acidosis: Monitor for signs of metabolic acidosis; decreased sodium bicarbonate with proximal tubule injury and renal wasting syndrome (including Fanconi syndrome), as well as metabolic acidosis with hepatic impairment and pancreatitis (including some fatal cases) have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Nephrotoxicity: <b>[US Boxed Warning]: Acute renal failure resulting in dialysis and/or contributing to death has occurred with as few as 1 or 2 doses of cidofovir. Renal function (serum creatinine and urine protein) must be monitored within 48 hours prior to each dose of cidofovir and the dose of cidofovir modified as appropriate.  Administration must be accompanied by oral probenecid and intravenous saline prehydration. </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Neutropenia: <b>[US Boxed Warning]: Neutropenia has been reported; monitor neutrophil counts during therapy. </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Ocular complications: Decreased intraocular pressure, sometimes associated with decreased visual acuity, uveitis, or iritis may occur; monitor intraocular pressure for and signs of iritis/uveitis during therapy. If uveitis or iritis occurs, consider treatment with topical corticosteroids with or without topical cycloplegic agents.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Contraindicated in patients with a baseline serum creatinine &gt;1.5 mg/dL, CrCl &le;55 mL/minute, or urine protein &ge;100 mg/dL (&ge;2+ proteinuria); dosage adjustment or discontinuation of therapy may be required for changes in renal function during treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Administration: For intravenous use only, <b>not</b> for direct intraocular injection; iritis, ocular hypotony, and permanent impairment of vision may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: <b>[US Boxed Warning]: Indicated only for CMV retinitis treatment in patients with AIDS.</b></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25855566\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Administration in children warrants extreme caution due to risk of long-term carcinogenicity and reproductive toxicity. A case of invasive squamous cell cancer has been reported in a pediatric patient receiving intralesional cidofovir for severe, recurrent respiratory papillomatosis; causality not established (Lott 2009). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299042\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Inhibits</b> MRP2</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F151262\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13155&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Cabozantinib: MRP2 Inhibitors may increase the serum concentration of Cabozantinib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tenofovir Products: Cidofovir may increase the serum concentration of Tenofovir Products. Tenofovir Products may increase the serum concentration of Cidofovir. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F151264\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F151276\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>[US Boxed Warning]: Possibly carcinogenic and teratogenic based on animal data. May cause hypospermia.</b> Women of childbearing potential should use effective contraception during therapy and for 1 month following treatment. Males should use a barrier contraceptive during therapy and for 3 months following treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">The indications for treating CMV retinitis during pregnancy are the same as in nonpregnant HIV infected woman; however systemic therapy should be avoided during the first trimester when possible. When therapy is needed to treat maternal infection, agents other than cidofovir are recommended (DHHS [Adult OI 2014]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046273\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor renal function (BUN, serum creatinine) within 48 hours prior to each dose, urinalysis (urine glucose and protein), CBC with differential (neutrophil count) prior to each dose, electrolytes (calcium, magnesium, phosphorus, uric acid), liver function tests (SGOT/SGPT), intraocular pressure and visual acuity, signs and symptoms of uveitis/iritis </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F151256\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Cidofovir is converted to cidofovir diphosphate (the active intracellular metabolite); cidofovir diphosphate suppresses CMV replication by selective inhibition of viral DNA synthesis. Incorporation of cidofovir diphosphate into growing viral DNA chain results in viral DNA synthesis rate reduction.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F151273\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:0em;display:inline\">The following pharmacokinetic data are based on a combination of cidofovir administered with probenecid:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: 0.41 L/kg; does not cross significantly into CSF</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: &lt;6%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Minimal; phosphorylation occurs intracellularly to the active metabolite cidofovir diphosphate</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination, plasma: ~2.6 hours; intracellular elimination half-lives of metabolites are longer (range: 24 to 87 hours) (Lea 1996)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (70% to 85% as unchanged drug)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Clearance:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Renal clearance without probenecid: 150 &plusmn; 26.9 mL/minute/1.73 m<sup>2</sup></p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Renal clearance with probenecid: 98.6 &plusmn; 27.9 mL/minute/1.73 m<sup>2</sup></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46170920\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">A 1% topical cidofovir gel may be prepared by using 5 mL of the 75 mg/mL cidofovir injection and combining with 32.5 mL of a propylene glycol-based jelly. Of note, propylene glycol may increase the absorption and bioavailability of cidofovir when used on abraded skin (McElhiney 2006).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323067\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Cidofovir Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">75 mg/mL (5 mL): $888.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038561\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Vistide (AT, AU, BE, BG, CH, CZ, DE, DK, FI, FR, GR, HN, HU, IE, IT, NL, NO, PL, PT, RO, RU, SE, SI, TR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Anderson EJ, Guzman-Cottrill JA, Kletzel M, et al, &quot;High-Risk Adenovirus-Infected Pediatric Allogeneic Hematopoietic Progenitor Cell Transplant Recipients and Preemptive Cidofovir Therapy,&quot; <i>Pediatr Transplant</i>, 2008, 12(2):219-27.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/18307672/pubmed\" target=\"_blank\" id=\"18307672\">18307672</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Araya CE, Garin EH, Neiberger RE, Dharnidharka VR. Leflunomide therapy for BK virus allograft nephropathy in pediatric and young adult kidney transplant recipients. <i>Pediatric Transplantation</i>. 2010;14:145-150.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/19344337/pubmed\" target=\"_blank\" id=\"19344337\">19344337</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Araya CE, Lew JF, Fennell RS, et al, &quot;Intermediate Dose Cidofovir Does Not Cause Additive Nephrotoxicity in BK Virus Allograft Nephropathy,&quot; <i>Pediatr Transplant</i>, 2008, 12(7):790-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/18537898/pubmed\" target=\"_blank\" id=\"18537898\">18537898</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bhadri VA, Lee-Horn L, Shaw PJ. Safety and tolerability of cidofovir in high-risk pediatric patients. <i>Transpl Infect Dis</i>. 2009;11(4):373-379.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/19392729/pubmed\" target=\"_blank\" id=\"19392729\">19392729</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bielecki I, Mniszek J, Cofala M. Intralesional injection of cidofovir for recurrent respiratory papillomatosis in children. <i>International Journal of Pediatric Otorhinolaryngology</i>. 2009;73:681-684.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/19193450/pubmed\" target=\"_blank\" id=\"19193450\">19193450</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cesaro S, Hirsch HH, Faraci M, et al. Cidofovir for BK virus-associated hemorrhagic cystitis: a retrospective study. <i>Clin Infect Dis</i>. 2009;49(2):233-240.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/19522651/pubmed\" target=\"_blank\" id=\"19522651\">19522651</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cesaro S, Pillon M, Tridello G, et.al. Relationship between clinical and BK virological response in patients with late hemorrhagic cysteitis treated with cidofovir, a retrospective study from the European Group for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i>. 2013;48:809-813.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/23222380/pubmed\" target=\"_blank\" id=\"23222380\">23222380</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cesaro S, Zhou X, Manzardo C, et al, &quot;Cidofovir for Cytomegalovirus Reactivation in Pediatric Patients After Hematopoietic Stem Cell Transplantation,&quot; <i>J Clin Virol</i>, 2005, 34(2):129-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/16157264/pubmed\" target=\"_blank\" id=\"16157264\">16157264</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS. Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. November 6, 2013. Available at <a href=\"http://aidsinfo.nih.gov/\" target=\"_blank\">http://aidsinfo.nih.gov</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS Panel on Opportunistic Infections (OI) in HIV-Infected Adults and Adolescents. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention (CDC), the National Institutes of Health (NIH), and the HIV Medicine Association (HIVMA) of the Infectious Diseases Society of America (IDSA). May 7, 2013. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Doan ML, Mallory GB, Kaplan SL, et al, &quot;Treatment of Adenovirus Pneumonia With Cidofovir in Pediatric Lung Transplant Recipients,&quot; <i>J Heart Lung Transplant</i>, 2007, 26(9):883-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/17845926/pubmed\" target=\"_blank\" id=\"17845926\">17845926</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ennis RD, Dahl TC. Stability of cidofovir in 0.9% sodium chloride injection for five days.<i> Am J Health Syst Pharm</i>. 1997;54(19):2204-2206.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/9331442 /pubmed\" target=\"_blank\" id=\"9331442 \">9331442 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Faraci M, Cuzzubbo D, Lanino E, et al, &quot;Low Dosage Cidofovir Without Probenecid as Treatment for BK Virus Hamorrhagic Cystitis After Hemopoietic Stem Cell Transplant,&quot; <i>Pediatr Infect Dis J</i>, 2009, 28(1):55-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/19057462/pubmed\" target=\"_blank\" id=\"19057462\">19057462</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gaziev J, Paba P, Miano R, et.al. Late-onset hemorrhagic cystitis in children after hematopoietic stem cell transplantation for thalassemia and sickle cell anemia: a prospective evaluation of polyoma (BK) virus infection and treatment with cidofovir. <i>Biol Blood Marrow Transplant</i>. 2010;16:662-671.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/20026413/pubmed\" target=\"_blank\" id=\"20026413\">20026413</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Graupp M, Gugatschka M, Kiesler K, Reckenzaun E, Hammer G, Friedrich G. Experience of 11 years use of cidofovir in recurrent respiratory papillomatosis. <i>Eur Arch Otorhinolaryngol</i>. 2013;270:641-646.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/23070260/pubmed\" target=\"_blank\" id=\"23070260\">23070260</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Legrand F, Berrebi D, Houhou N, et al, &ldquo;Early Diagnosis of Adenovirus Infection and Treatment With Cidofovir After Bone Marrow Transplantation in Children,&rdquo; <i>Bone Marrow Transplant</i>, 2001, 27(6):621-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/11319592/pubmed\" target=\"_blank\" id=\"11319592\">11319592</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lott DG, Krakovitz PR. Squamous cell carcinoma associated with intralesional injection of cidofovir for recurrent respiratory papillomatosis.<i> The Laryngoscope</i>. 2009;119:567-570.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/19235765/pubmed\" target=\"_blank\" id=\"19235765\">19235765</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Megged O, Stein J, Ben-Meir D, Shulman LM, Yaniv I, Shalit I, Levy I. BK-virus-associated hemorrhagic cystitis in children after hematopoietic stem cell transplantation. <i>J Pediatr Hematol Oncol</i>. 2011;33:190-193.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/21325972/pubmed\" target=\"_blank\" id=\"21325972\">21325972</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Naiman AN, Ayari S, Nicollas R, et al, &quot;Intermediate-Term and Long-Term Results After Treatment by Cidofovir and Excision in Juvenile Laryngeal Papillomatosis,&quot; <i>Ann Otol Rhinol Laryngol</i>, 2006, 115(9):667-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/17044537/pubmed\" target=\"_blank\" id=\"17044537\">17044537</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Valera F, Maldonato L, Lima J, et.al. Efficacy of cidofovir in recurrent juvenile respiratory papillomatosis. <i>Braz J Otorhinolaryngol</i>. 2010;76(6):713-717.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/21180938/pubmed\" target=\"_blank\" id=\"21180938\">21180938</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vistide (cidofovir) [prescribing information]. Foster City, CA: Gilead; September 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wierzbicka M, Jackowska J, Bartochowska A, J&oacute;zefiak A, Szyfter W, K&#281;dzia W. Effectiveness of cidofovir intralesional treatment in recurrent respiratory papillomatosis. <i>Eur Arch Otorhinolaryngol</i>. 2011;268:1305-1311.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/21519834/pubmed\" target=\"_blank\" id=\"21519834\">21519834</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Williams KM, Agwu AL, Dabb AA, et al, &quot;A Clinical Algorithm Identifies High Risk Pediatric Oncology and Bone Marrow Transplant Patients Likely to Benefit From Treatment of Adenoviral Infection,&quot; <i>J Pediatr Hematol Oncol</i>, 2009, 31(11):825-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/19801951/pubmed\" target=\"_blank\" id=\"19801951\">19801951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yusuf U, Hale GA, Carr J, et al, &quot;Cidofovir for the Treatment of Adenoviral Infection in Pediatric Hematopoietic Stem Cell Transplant Patients,&quot; <i>Transplantation</i>, 2006, 81(10):1398-404.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cidofovir-pediatric-drug-information/abstract-text/16732176/pubmed\" target=\"_blank\" id=\"16732176\">16732176</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13155 Version 114.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708672\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F151289\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1046274\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1046266\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F151268\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F151253\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1046277\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49130930\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F151283\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1046276\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F151319\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F151274\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F151257\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25855566\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299042\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F151262\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F151264\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F151276\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1046273\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F151256\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F151273\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F46170920\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323067\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038561\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13155|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=cidofovir-drug-information\" class=\"drug drug_general\">Cidofovir: Drug information</a></li><li><a href=\"topic.htm?path=cidofovir-patient-drug-information\" class=\"drug drug_patient\">Cidofovir: Patient drug information</a></li></ul></div></div>","javascript":null}